Brought to you by 
Genentech licenses TolerRx's TRX1 for autoimmune disease
21 Jun 2004
Executive Summary
Genentech licensed exclusive worldwide rights to TolerRx's (developing therapeutics that either induce or take away the body's immune response) Phase I TRX1, an antibody with potential for treating autoimmune disease.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com